Advancements

Advancements

Advancements

The engineering team at Flowonix has a rich history of developing the technology to efficiently deliver medication when a patient needs it most.

Our team continues to innovate and is proud to hold 12 issued patents and an additional 7 patents pending. A leader in the industry, our team has been responsible for many early drug delivery systems, including:

  • First implant for anticoagulant Heparin
  • First human implant for Floxuridine (FUDR, an anti-cancer chemotherapy drug)
  • First human implant for insulin
  • First human implant for morphine
  • First valve regulated intrathecal pump
  • US Patents on:
    • Programmable valve pumps
    • Implantable, refillable pumps
    • Long life power supplies for implantable pumps
    • Septumless implantable pumps
    • Low power electromagnetic valves
    • Pump diagnostic systems


U.S. Patents:

Implantable Pump Connector for Catheter Attachment - 7,452,354
Implantable Pump Connector for Catheter Attachment - 7,927,325     
MRI Compatible Programmable Valve Pump -7,828,702
Implantable Refillable Infusion Device - 6,764,472
Implantable Refillable Infusion Device and Septum Replacement Kit - 7,108,686
Two-Way Accumulator Programmable Valve Pump - 8,273,058
Two-Way Accumulator Programmable Valve Pump - 8,696,627
Multiple Reservoir Implantable Drug Infusion Device and Method - 8,545,477
Multiple Reservoir Implantable Drug Infusion Device and Method - 8,551,044

Patent Applications:
Methods and Systems for Providing Metered Doses of a Compound to an Individual - 2011-0060318
Implantable Drug Delivery System Having Periodic Drug Delivery Regimen to Avoid Granulomas - 2010-0152713
Additional non-published patent applications are pending 

For more information on Prometra®, contact Flowonix